ID   EPHB2_HUMAN             Reviewed;        1055 AA.
AC   P29323; O43477; Q5T0U6; Q5T0U7; Q5T0U8;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 5.
DT   02-NOV-2010, entry version 142.
DE   RecName: Full=Ephrin type-B receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=DRT;
DE   AltName: Full=EPH-like kinase 5;
DE            Short=EK5;
DE            Short=hEK5;
DE   AltName: Full=ERK;
DE   AltName: Full=Renal carcinoma antigen NY-REN-47;
DE   AltName: Full=Tyrosine-protein kinase TYRO5;
DE   AltName: Full=Tyrosine-protein kinase receptor EPH-3;
DE   Flags: Precursor;
GN   Name=EPHB2; Synonyms=DRT, EPHT3, EPTH3, ERK, HEK5, TYRO5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8033077;
RA   Kiyokawa E., Takai S., Tanaka M., Iwase T., Suzuki M., Xiang Y.Y.,
RA   Naito Y., Yamada K., Sugimura H., Kino I.;
RT   "Overexpression of ERK, an EPH family receptor protein tyrosine
RT   kinase, in various human tumors.";
RL   Cancer Res. 54:3645-3650(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Fetal brain;
RX   MEDLINE=96154673; PubMed=8589679; DOI=10.1093/hmg/4.11.2033;
RA   Ikegaki N., Tang X.X., Liu X.-G., Biegel J.A., Allen C., Yoshioka A.,
RA   Sulman E.P., Brodeur G.M., Pleasure D.E.;
RT   "Molecular characterization and chromosomal localization of DRT
RT   (EPHT3): a developmentally regulated human protein-tyrosine kinase
RT   gene of the EPH family.";
RL   Hum. Mol. Genet. 4:2033-2045(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   MEDLINE=98359217; PubMed=9696046; DOI=10.1038/sj.onc.1201960;
RA   Tang X.X., Pleasure D.E., Brodeur G.M., Ikegaki N.;
RT   "A variant transcript encoding an isoform of the human protein
RT   tyrosine kinase EPHB2 is generated by alternative splicing and
RT   alternative use of polyadenylation signals.";
RL   Oncogene 17:521-526(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-986 (ISOFORM 2).
RC   TISSUE=Brain;
RX   MEDLINE=95206782; PubMed=7898931;
RA   Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M.,
RA   Basu R., Welcher A.A.;
RT   "cDNA cloning and tissue distribution of five human EPH-like receptor
RT   protein-tyrosine kinases.";
RL   Oncogene 10:897-905(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 509-986 (ISOFORM 2).
RC   TISSUE=Fetal brain;
RX   MEDLINE=95324932; PubMed=7601466; DOI=10.1016/0888-7543(95)80224-A;
RA   Saito T., Seki N., Matsuda Y., Kitahara M., Murata M., Kanda N.,
RA   Nomura N., Yamamoto T., Hori T.-A.;
RT   "Identification of the human ERK gene as a putative receptor tyrosine
RT   kinase and its chromosomal localization to 1p36.1: a comparative
RT   mapping of human, mouse, and rat chromosomes.";
RL   Genomics 26:382-384(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 640-986 (ISOFORM 2).
RC   TISSUE=Gastric carcinoma;
RX   MEDLINE=93343925; PubMed=7688222; DOI=10.1006/bbrc.1993.1878;
RA   Iwase T., Tanaka M., Suzuki M., Naito Y., Sugimura H., Kino I.;
RT   "Identification of protein-tyrosine kinase genes preferentially
RT   expressed in embryo stomach and gastric cancer.";
RL   Biochem. Biophys. Res. Commun. 194:698-705(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 652-712.
RX   MEDLINE=91296384; PubMed=1648701;
RA   Chan J., Watt V.M.;
RT   "eek and erk, new members of the eph subclass of receptor protein-
RT   tyrosine kinases.";
RL   Oncogene 6:1057-1061(1991).
RN   [9]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   MEDLINE=99438124; PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-596 AND TYR-602, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=15951569; DOI=10.1074/mcp.M500089-MCP200;
RA   Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,
RA   Lauffenburger D.A., White F.M.;
RT   "Time-resolved mass spectrometry of tyrosine phosphorylation sites in
RT   the epidermal growth factor receptor signaling network reveals dynamic
RT   modules.";
RL   Mol. Cell. Proteomics 4:1240-1250(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-775, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-596, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-776 AND TYR-780, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-602 AND TYR-780, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-148; TYR-596; TYR-602;
RP   THR-775; SER-776; THR-779; TYR-780; SER-897 AND SER-983, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 910-986 (ISOFORM SHORT).
RX   MEDLINE=99132419; PubMed=9933164; DOI=10.1126/science.283.5403.833;
RA   Thanos C.D., Goodwill K.E., Bowie J.U.;
RT   "Oligomeric structure of the human EphB2 receptor SAM domain.";
RL   Science 283:833-836(1999).
RN   [17]
RP   VARIANTS PROSTATE CANCER HIS-199; SER-279; ASN-679 AND MET-909, AND
RP   FUNCTION AS A TUMOR SUPPRESSOR.
RX   PubMed=15300251; DOI=10.1038/ng1408;
RA   Huusko P., Ponciano-Jackson D., Wolf M., Kiefer J.A., Azorsa D.O.,
RA   Tuzmen S., Weaver D., Robbins C., Moses T., Allinen M., Hautaniemi S.,
RA   Chen Y., Elkahloun A., Basik M., Bova G.S., Bubendorf L., Lugli A.,
RA   Sauter G., Schleutker J., Ozcelik H., Elowe S., Pawson T., Trent J.M.,
RA   Carpten J.D., Kallioniemi O.-P., Mousses S.;
RT   "Nonsense-mediated decay microarray analysis identifies mutations of
RT   EPHB2 in human prostate cancer.";
RL   Nat. Genet. 36:979-983(2004).
RN   [18]
RP   VARIANTS PROSTATE CANCER SER-279; ALA-650 AND VAL-883.
RX   PubMed=16155194; DOI=10.1136/jmg.2005.035790;
RA   Kittles R.A., Baffoe-Bonnie A.B., Moses T.Y., Robbins C.M.,
RA   Ahaghotu C., Huusko P., Pettaway C., Vijayakumar S., Bennett J.,
RA   Hoke G., Mason T., Weinrich S., Trent J.M., Collins F.S., Mousses S.,
RA   Bailey-Wilson J., Furbert-Harris P., Dunston G., Powell I.J.,
RA   Carpten J.D.;
RT   "A common nonsense mutation in EphB2 is associated with prostate
RT   cancer risk in African American men with a positive family history.";
RL   J. Med. Genet. 43:507-511(2006).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-279; GLY-289; VAL-361; ASN-678 AND
RP   TRP-844.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for members of the ephrin-B family. Acts as a
CC       tumor suppressor.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: The ligand-activated form interacts with multiple
CC       proteins, including GTPase-activating protein (RASGAP) through its
CC       SH2 domain. Binds RASGAP through the juxtamembrane tyrosines
CC       residues. Interacts with PRKCABP and GRIP1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=EPHB2v, Long;
CC         IsoId=P29323-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P29323-2; Sequence=VSP_003016, VSP_003017;
CC       Name=3;
CC         IsoId=P29323-3; Sequence=VSP_015713, VSP_003016, VSP_003017;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Brain, heart, lung, kidney, placenta,
CC       pancreas, liver and skeletal muscle. Preferentially expressed in
CC       fetal brain.
CC   -!- DISEASE: Defects in EPHB2 may be a cause of susceptibility to
CC       prostate cancer (PC) [MIM:176807]. It is a malignancy originating
CC       in tissues of the prostate. Most prostate cancers are
CC       adenocarcinomas that develop in the acini of the prostatic ducts.
CC       Other rare histopathologic types of prostate cancer that occur in
CC       approximately 5% of patients include small cell carcinoma,
CC       mucinous carcinoma, prostatic ductal carcinoma, transitional cell
CC       carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid
CC       cystic carcinoma (basaloid), signet-ring cell carcinoma and
CC       neuroendocrine carcinoma.
CC   -!- DISEASE: Defects in EPHB2 are involved in the development of
CC       prostate cancer metastasis to the brain [MIM:603688].
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SAM (sterile alpha motif) domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D31661; BAA06506.1; -; mRNA.
DR   EMBL; L41939; AAA99310.1; -; mRNA.
DR   EMBL; AF025304; AAB94602.1; -; mRNA.
DR   EMBL; AL035704; CAI22645.1; -; Genomic_DNA.
DR   EMBL; AL158086; CAI22645.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22645.1; JOINED; Genomic_DNA.
DR   EMBL; AL035704; CAI22646.1; -; Genomic_DNA.
DR   EMBL; AL158086; CAI22646.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22646.1; JOINED; Genomic_DNA.
DR   EMBL; AL035704; CAI22647.2; -; Genomic_DNA.
DR   EMBL; AL158086; CAI22647.2; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22647.2; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI22897.1; -; Genomic_DNA.
DR   EMBL; AL035704; CAI22897.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22897.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI22898.1; -; Genomic_DNA.
DR   EMBL; AL512444; CAI22898.1; JOINED; Genomic_DNA.
DR   EMBL; AL035704; CAI22898.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI22899.2; -; Genomic_DNA.
DR   EMBL; AL035704; CAI22899.2; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22899.2; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI16428.1; -; Genomic_DNA.
DR   EMBL; AL035704; CAI16428.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI16428.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI16429.1; -; Genomic_DNA.
DR   EMBL; AL035704; CAI16429.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI16429.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI16430.2; -; Genomic_DNA.
DR   EMBL; AL035704; CAI16430.2; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI16430.2; JOINED; Genomic_DNA.
DR   EMBL; L36643; AAA74244.1; -; mRNA.
DR   EMBL; D37827; BAA07073.1; -; mRNA.
DR   EMBL; D14717; BAA03537.1; -; mRNA.
DR   EMBL; X59292; CAA41981.1; -; Genomic_DNA.
DR   IPI; IPI00021275; -.
DR   IPI; IPI00219421; -.
DR   IPI; IPI00252979; -.
DR   PIR; A57174; A57174.
DR   PIR; I78842; I78842.
DR   RefSeq; NP_004433.2; -.
DR   RefSeq; NP_059145.2; -.
DR   UniGene; Hs.523329; -.
DR   PDB; 1B4F; X-ray; 1.95 A; A/B/C/D/E/F/G/H=910-985.
DR   PDB; 1F0M; X-ray; 2.20 A; A=910-985.
DR   PDB; 2QBX; X-ray; 2.30 A; A/B=20-196.
DR   PDBsum; 1B4F; -.
DR   PDBsum; 1F0M; -.
DR   PDBsum; 2QBX; -.
DR   ProteinModelPortal; P29323; -.
DR   SMR; P29323; 321-437, 323-526, 439-531, 594-892.
DR   DIP; DIP-1162N; -.
DR   IntAct; P29323; 8.
DR   MINT; MINT-5005955; -.
DR   STRING; P29323; -.
DR   PhosphoSite; P29323; -.
DR   PRIDE; P29323; -.
DR   Ensembl; ENST00000400191; ENSP00000383053; ENSG00000133216.
DR   GeneID; 2048; -.
DR   KEGG; hsa:2048; -.
DR   UCSC; uc001bge.1; human.
DR   UCSC; uc001bgf.1; human.
DR   UCSC; uc009vqj.1; human.
DR   CTD; 2048; -.
DR   GeneCards; GC01P023037; -.
DR   H-InvDB; HIX0028518; -.
DR   HGNC; HGNC:3393; EPHB2.
DR   HPA; CAB013647; -.
DR   MIM; 176807; phenotype.
DR   MIM; 600997; gene.
DR   MIM; 603688; phenotype.
DR   Orphanet; 1331; Familial prostate cancer.
DR   PharmGKB; PA27825; -.
DR   eggNOG; maNOG13770; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P29323; -.
DR   OMA; ELGWIVH; -.
DR   PhylomeDB; P29323; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; ephbfwdpathway; EPHB forward signaling.
DR   Pathway_Interaction_DB; ephrinbrevpathway; Ephrin B reverse signaling.
DR   Pathway_Interaction_DB; ephrinb_ephbpathway; EphrinB-EPHB pathway.
DR   Pathway_Interaction_DB; syndecan_2_pathway; Syndecan-2-mediated signaling events.
DR   Reactome; REACT_18266; Axon guidance.
DR   NextBio; 8325; -.
DR   ArrayExpress; P29323; -.
DR   Bgee; P29323; -.
DR   CleanEx; HS_EPHB2; -.
DR   Genevestigator; P29323; -.
DR   GermOnline; ENSG00000133216; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; TAS:UniProtKB.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM_type.
DR   InterPro; IPR021129; SAM_type1.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR010993; Sterile_alpha_motif_homology.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR020769; Tyr_prot_kinase_EphB_rcpt.
DR   InterPro; IPR016257; Tyr_prot_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_prot_kinase_rcpt_V_CS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 2.
DR   Gene3D; G3DSA:1.10.150.50; SAM_type; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF279; Tyr_prot_kinase_EphB_rcpt; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07699; GCC2_GCC3; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; FN_III-like; 2.
DR   SUPFAM; SSF49785; Gal_bind_like; 1.
DR   SUPFAM; SSF57184; Grow_fac_recept; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF47769; SAM_homology; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tumor suppressor;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     18       Potential.
FT   CHAIN        19   1055       Ephrin type-B receptor 2.
FT                                /FTId=PRO_0000016827.
FT   TOPO_DOM     19    543       Extracellular (Potential).
FT   TRANSMEM    544    564       Helical; (Potential).
FT   TOPO_DOM    565   1055       Cytoplasmic (Potential).
FT   DOMAIN      325    426       Fibronectin type-III 1.
FT   DOMAIN      432    527       Fibronectin type-III 2.
FT   DOMAIN      621    884       Protein kinase.
FT   DOMAIN      913    977       SAM.
FT   NP_BIND     627    635       ATP (By similarity).
FT   MOTIF       984    986       PDZ-binding (in isoform 2) (Potential).
FT   COMPBIAS    184    324       Cys-rich.
FT   ACT_SITE    746    746       Proton acceptor (By similarity).
FT   BINDING     653    653       ATP (By similarity).
FT   MOD_RES     148    148       Phosphoserine.
FT   MOD_RES     596    596       Phosphotyrosine.
FT   MOD_RES     602    602       Phosphotyrosine.
FT   MOD_RES     775    775       Phosphothreonine.
FT   MOD_RES     776    776       Phosphoserine.
FT   MOD_RES     779    779       Phosphothreonine.
FT   MOD_RES     780    780       Phosphotyrosine.
FT   MOD_RES     897    897       Phosphoserine.
FT   MOD_RES     983    983       Phosphoserine.
FT   CARBOHYD    265    265       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    336    336       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    428    428       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    482    482       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ     568    568       R -> RR (in isoform 3).
FT                                /FTId=VSP_015713.
FT   VAR_SEQ     986    986       G -> V (in isoform 2 and isoform 3).
FT                                /FTId=VSP_003016.
FT   VAR_SEQ     987   1055       Missing (in isoform 2 and isoform 3).
FT                                /FTId=VSP_003017.
FT   VARIANT     199    199       R -> H (in prostate cancer).
FT                                /FTId=VAR_032853.
FT   VARIANT     279    279       A -> S (in prostate cancer;
FT                                dbSNP:rs35882952).
FT                                /FTId=VAR_032854.
FT   VARIANT     289    289       C -> G.
FT                                /FTId=VAR_042172.
FT   VARIANT     361    361       I -> V (in dbSNP:rs56180036).
FT                                /FTId=VAR_042173.
FT   VARIANT     650    650       V -> A (in prostate cancer).
FT                                /FTId=VAR_032855.
FT   VARIANT     678    678       D -> N (in dbSNP:rs28936395).
FT                                /FTId=VAR_042174.
FT   VARIANT     679    679       H -> N (in prostate cancer).
FT                                /FTId=VAR_032856.
FT   VARIANT     844    844       R -> W (in dbSNP:rs55826626).
FT                                /FTId=VAR_042175.
FT   VARIANT     883    883       M -> V (in prostate cancer).
FT                                /FTId=VAR_032857.
FT   VARIANT     909    909       I -> M (in prostate cancer).
FT                                /FTId=VAR_032858.
FT   CONFLICT      1     20       MALRRLGAALLLLPLLAAVE -> MWVPVLALPVCTYA
FT                                (in Ref. 1; BAA06506).
FT   CONFLICT    154    154       G -> D (in Ref. 1; BAA06506).
FT   CONFLICT    476    476       K -> KQ (in Ref. 1; BAA06506).
FT   CONFLICT    495    496       Missing (in Ref. 5; AAA74244).
FT   CONFLICT    532    532       E -> D (in Ref. 1; BAA06506).
FT   CONFLICT    589    589       M -> I (in Ref. 5; AAA74244).
FT   CONFLICT    671    671       A -> R (in Ref. 7; BAA03537).
FT   CONFLICT    788    788       I -> F (in Ref. 5; AAA74244).
FT   CONFLICT    853    853       S -> A (in Ref. 1; BAA06506, 6; BAA07073
FT                                and 7; BAA03537).
FT   CONFLICT    923    923       E -> K (in Ref. 1; BAA06506, 6; BAA07073
FT                                and 7; BAA03537).
FT   CONFLICT    958    958       V -> L (in Ref. 2; AAA99310).
FT   STRAND       21     25
FT   HELIX        26     28
FT   STRAND       36     39
FT   STRAND       44     49
FT   STRAND       55     61
FT   STRAND       66     68
FT   STRAND       71     74
FT   STRAND       84     94
FT   HELIX        97     99
FT   STRAND      111    120
FT   STRAND      130    132
FT   STRAND      135    141
FT   STRAND      148    152
FT   STRAND      155    166
FT   STRAND      171    183
FT   STRAND      185    194
FT   HELIX       918    924
FT   HELIX       928    930
FT   HELIX       931    936
FT   HELIX       942    945
FT   HELIX       950    955
FT   HELIX       961    982
SQ   SEQUENCE   1055 AA;  117493 MW;  4F8BFEDC45986483 CRC64;
     MALRRLGAAL LLLPLLAAVE ETLMDSTTAT AELGWMVHPP SGWEEVSGYD ENMNTIRTYQ
     VCNVFESSQN NWLRTKFIRR RGAHRIHVEM KFSVRDCSSI PSVPGSCKET FNLYYYEADF
     DSATKTFPNW MENPWVKVDT IAADESFSQV DLGGRVMKIN TEVRSFGPVS RSGFYLAFQD
     YGGCMSLIAV RVFYRKCPRI IQNGAIFQET LSGAESTSLV AARGSCIANA EEVDVPIKLY
     CNGDGEWLVP IGRCMCKAGF EAVENGTVCR GCPSGTFKAN QGDEACTHCP INSRTTSEGA
     TNCVCRNGYY RADLDPLDMP CTTIPSAPQA VISSVNETSL MLEWTPPRDS GGREDLVYNI
     ICKSCGSGRG ACTRCGDNVQ YAPRQLGLTE PRIYISDLLA HTQYTFEIQA VNGVTDQSPF
     SPQFASVNIT TNQAAPSAVS IMHQVSRTVD SITLSWSQPD QPNGVILDYE LQYYEKELSE
     YNATAIKSPT NTVTVQGLKA GAIYVFQVRA RTVAGYGRYS GKMYFQTMTE AEYQTSIQEK
     LPLIIGSSAA GLVFLIAVVV IAIVCNRRGF ERADSEYTDK LQHYTSGHMT PGMKIYIDPF
     TYEDPNEAVR EFAKEIDISC VKIEQVIGAG EFGEVCSGHL KLPGKREIFV AIKTLKSGYT
     EKQRRDFLSE ASIMGQFDHP NVIHLEGVVT KSTPVMIITE FMENGSLDSF LRQNDGQFTV
     IQLVGMLRGI AAGMKYLADM NYVHRDLAAR NILVNSNLVC KVSDFGLSRF LEDDTSDPTY
     TSALGGKIPI RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM TNQDVINAIE
     QDYRLPPPMD CPSALHQLML DCWQKDRNHR PKFGQIVNTL DKMIRNPNSL KAMAPLSSGI
     NLPLLDRTIP DYTSFNTVDE WLEAIKMGQY KESFANAGFT SFDVVSQMMM EDILRVGVTL
     AGHQKKILNS IQVMRAQMNQ IQSVEGQPLA RRPRATGRTK RCQPRDVTKK TCNSNDGKKK
     GMGKKKTDPG RGREIQGIFF KEDSHKESND CSCGG
//
